PL3445744T3 - Nowe inhibitory mepryny alfa i beta - Google Patents

Nowe inhibitory mepryny alfa i beta

Info

Publication number
PL3445744T3
PL3445744T3 PL17719214T PL17719214T PL3445744T3 PL 3445744 T3 PL3445744 T3 PL 3445744T3 PL 17719214 T PL17719214 T PL 17719214T PL 17719214 T PL17719214 T PL 17719214T PL 3445744 T3 PL3445744 T3 PL 3445744T3
Authority
PL
Poland
Prior art keywords
new
beta inhibitors
meprin alpha
meprin
alpha
Prior art date
Application number
PL17719214T
Other languages
English (en)
Inventor
Michael Wermann
Mirko Buchholz
Hans-Ulrich Demuth
Daniel Ramsbeck
Dagmar Schlenzig
Stephan Schilling
Original Assignee
Vivoryon Therapeutics Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivoryon Therapeutics Ag filed Critical Vivoryon Therapeutics Ag
Publication of PL3445744T3 publication Critical patent/PL3445744T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C239/00—Compounds containing nitrogen-to-halogen bonds; Hydroxylamino compounds or ethers or esters thereof
    • C07C239/08—Hydroxylamino compounds or their ethers or esters
    • C07C239/18—Hydroxylamino compounds or their ethers or esters having nitrogen atoms of hydroxylamino groups further bound to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A61K31/36—Compounds containing methylenedioxyphenyl groups, e.g. sesamin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/58—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and singly-bound nitrogen atoms, not being further bound to other hetero atoms, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/06—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/36—Radicals substituted by singly-bound nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/50—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/58—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/64—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyrrole Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
PL17719214T 2016-04-18 2017-04-18 Nowe inhibitory mepryny alfa i beta PL3445744T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP16165804 2016-04-18
EP17719214.3A EP3445744B1 (en) 2016-04-18 2017-04-18 Novel inhibitors of meprin alpha and beta
PCT/EP2017/059116 WO2017182433A1 (en) 2016-04-18 2017-04-18 Novel inhibitors of meprin alpha and beta

Publications (1)

Publication Number Publication Date
PL3445744T3 true PL3445744T3 (pl) 2022-02-07

Family

ID=55808391

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17719214T PL3445744T3 (pl) 2016-04-18 2017-04-18 Nowe inhibitory mepryny alfa i beta

Country Status (12)

Country Link
US (2) US10975019B2 (pl)
EP (2) EP3445744B1 (pl)
JP (3) JP2019519477A (pl)
KR (2) KR102511732B1 (pl)
CN (2) CN114507175B (pl)
AU (2) AU2017253625B2 (pl)
CA (1) CA3021152A1 (pl)
DK (1) DK3445744T3 (pl)
ES (1) ES2903079T3 (pl)
PL (1) PL3445744T3 (pl)
RU (1) RU2746850C2 (pl)
WO (1) WO2017182433A1 (pl)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3445744T3 (pl) * 2016-04-18 2022-02-07 Vivoryon Therapeutics Ag Nowe inhibitory mepryny alfa i beta
EP3750878B1 (en) * 2019-06-14 2025-05-14 Vivoryon Therapeutics N.V. Heteroaromatic inhibitors of astacin proteinases
BR112021025877A2 (pt) * 2019-06-26 2022-02-08 Enyo Pharma Derivados de amina terciária e seus usos para tratar uma infecção viral
SE547538C2 (en) 2024-05-10 2025-10-14 Peanta Invent Ab Light head for use in relining pipes

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5639746A (en) * 1994-12-29 1997-06-17 The Procter & Gamble Company Hydroxamic acid-containing inhibitors of matrix metalloproteases
ES2178759T3 (es) * 1996-10-02 2003-01-01 Novartis Ag Derivados de acido hidroxamico.
EP1027042A4 (en) * 1997-09-29 2004-08-18 Bristol Myers Squibb Co FARNESYL PROTEIN TRANSFERASE INHIBITORS
US6583299B1 (en) * 1999-05-20 2003-06-24 G.D. Searle & Co. α-amino-β-sulfonyl hydroxamic acid compounds
US20010049449A1 (en) * 1999-12-23 2001-12-06 Becker Daniel P. Aromatic sulfonyl alpha-cycloamino hydroxamates and their use as MMP inhibitors
AU2001279649A1 (en) 2000-06-08 2001-12-17 Jomaa Pharmaka Gmbh Use of organophosphorous hydroxamic acid derivatives for producing medicaments
AU2001279648A1 (en) * 2000-06-08 2001-12-17 Jomaa Pharmaka Gmbh Organophosphorous hydroxamic acid derivatives used as herbicides
CA2492035A1 (en) 2002-07-11 2004-01-15 Vicuron Pharmaceuticals, Inc. N-hydroxyamide derivatives possessing antibacterial activity
ES2387803T3 (es) * 2003-01-08 2012-10-02 Novartis Vaccines And Diagnostics, Inc. Agentes antibacterianos
US7662856B2 (en) * 2003-08-29 2010-02-16 The University Of Houston System Compositions having antimycrobial activity including a hydroxamate or a hydroxamate and a hydroxlyamine
WO2005073180A1 (ja) 2003-12-25 2005-08-11 Kureha Corporation ヒドロキサム酸誘導体、及び該誘導体を含むａｇｅ生成阻害剤
MX2007001337A (es) 2004-08-02 2008-03-13 Genmedica Therapeutics Sl Compuestos para inhibir amina-oxidasas que contienen cobre y usos de los mismos.
WO2007003594A1 (en) 2005-07-01 2007-01-11 Solvay Pharmaceuticals Gmbh Screening methods for inhibitors of the metalloprotease meprin
US20070066646A1 (en) * 2005-08-02 2007-03-22 Genmedica Therapeutics Sl Compounds for Inhibiting Copper-Containing Amine Oxidases and Uses Thereof
US20080161320A1 (en) * 2006-09-11 2008-07-03 Xiong Cai Fused bicyclic pyrimidines as ptk inhibitors containing a zinc binding moiety
US8119692B2 (en) * 2007-04-02 2012-02-21 Panthera Biopharma Llc Hydroxamic acid derivatives of 4-phenyl 4-hydroxy, 4-phenyl 4-alkoxy and 4-phenyl 4-arylalkoxy butyric acid useful as therapeutic agents for treating anthrax poisoning
CA2691987C (en) * 2007-06-12 2016-08-16 Achaogen, Inc. Antibacterial agents
WO2009036057A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Antiproliferative agents containing a zinc binding moiety
TW200920357A (en) * 2007-09-10 2009-05-16 Curis Inc HSP90 inhibitors containing a zinc binding moiety
WO2015024011A2 (en) 2013-08-16 2015-02-19 Duke University Antibacterial compounds
US9708336B2 (en) * 2014-01-22 2017-07-18 Merck Sharp & Dohme Corp. Metallo-beta-lactamase inhibitors
CN105237478A (zh) 2015-11-06 2016-01-13 吉首大学 一类甲硝唑-酰胺衍生物尿素酶抑制剂及其合成和用途
PL3445744T3 (pl) 2016-04-18 2022-02-07 Vivoryon Therapeutics Ag Nowe inhibitory mepryny alfa i beta

Also Published As

Publication number Publication date
JP2021102645A (ja) 2021-07-15
JP7179114B2 (ja) 2022-11-28
US12378186B2 (en) 2025-08-05
US20210198189A1 (en) 2021-07-01
JP2023129525A (ja) 2023-09-14
KR102410199B1 (ko) 2022-06-17
CN114507175B (zh) 2024-10-01
EP3445744B1 (en) 2021-10-06
WO2017182433A1 (en) 2017-10-26
EP3967679C0 (en) 2025-02-19
JP7739365B2 (ja) 2025-09-16
US20190127317A1 (en) 2019-05-02
KR20220003139A (ko) 2022-01-07
EP3967679A1 (en) 2022-03-16
RU2746850C2 (ru) 2021-04-21
AU2017253625B2 (en) 2021-08-12
EP3445744A1 (en) 2019-02-27
RU2021110237A (ru) 2021-05-06
AU2021257905B2 (en) 2023-03-02
KR102511732B1 (ko) 2023-03-17
EP3967679B1 (en) 2025-02-19
JP2019519477A (ja) 2019-07-11
RU2018140207A (ru) 2020-05-19
CA3021152A1 (en) 2017-10-26
AU2017253625A1 (en) 2018-11-22
CN109195947A (zh) 2019-01-11
RU2018140207A3 (pl) 2020-05-19
KR20180135002A (ko) 2018-12-19
CN114507175A (zh) 2022-05-17
CN109195947B (zh) 2022-03-04
ES2903079T3 (es) 2022-03-31
AU2021257905A1 (en) 2021-11-18
DK3445744T3 (da) 2021-12-13
US10975019B2 (en) 2021-04-13

Similar Documents

Publication Publication Date Title
IL283639A (en) Kif18a inhibitors
IL269196A (en) Novel inhibitors
PL3468966T3 (pl) Inhibitory interakcji menina-mll
PL3621960T3 (pl) Tienopirydyny i benzotiofeny użyteczne jako inhibitory irak4
PL3303654T3 (pl) Podstawione w pozycji 2 benzimidazolowe inhibitory korozji
IL280863A (en) Autotaxin inhibitors and uses thereof
PL3154989T3 (pl) Inhibitory beta-laktamaz
LT3497103T (lt) Piridopirimidinono cdk2/4/6 inhibitoriai
DK3571192T3 (da) Jak1-selektive inhibitorer
DK3389658T3 (da) Glycosidasehæmmere og anvendelser deraf
DK3442972T3 (da) Bromdomænehæmmere
LT3303334T (lt) Tirozinkinazės inhibitoriai
HRP20181941T1 (hr) Alat za njegu i postupak
PL3509591T3 (pl) Nowe selektywne inhibitory Jak1 i ich zastosowanie
DK3538528T3 (da) Pyrrolamider som alpha v-integrinhæmmere
PL3426244T3 (pl) Inhibitory dehydrogenazy 3-fosfoglicerynianowej i ich zastosowania
DK3543240T3 (da) URAT1-inhibitor og anvendelse deraf
DK3474883T3 (da) Komplementinhibitorer og anvendelser deraf
DK3668955T3 (da) Korrosionsinhibitor
DK3630744T3 (da) Pyrazol-magl-inhibitorer
PL3672948T3 (pl) Związki pirydynoamino-pirydonu i pirymidynoamino-pirydonu
DK3190569T3 (da) Adgangsstyringssystem til anvendelse i områder med adgangsbegrænsning og industrielle miljøer
IL281514A (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
EP3768272A4 (en) JAK HEMMER
BR112016023299A2 (pt) Composto tricíclico e inibidor de jak